Published in:
01-02-2017 | Editorial
What do we know? What do we need to know?
Authors:
Milena J. Henzlova, MD, W. Lane Duvall, MD
Published in:
Journal of Nuclear Cardiology
|
Issue 1/2017
Login to get access
Excerpt
Nuclear cardiology experienced unprecedented growth in the 1980-1990’s after the introduction of SPECT technology, development of Tc-99m-based tracers,
1 and utilization of coronary vasodilators for pharmacologic stress.
2-
4 During the late part of the last century, nuclear cardiology became a dominant physiologic and noninvasive method for the diagnosis, risk stratification, and prognostication of epicardial coronary artery disease (CAD). However, the arrival of competing diagnostic modalities used for similar indications, such as coronary CT angiography and stress echocardiography, unmasked weaknesses of the radionuclide methods, particularly the length of the procedure, relatively high radiation doses for a diagnostic test,
5,
6 and possible underestimation of the extent of the disease.
7 …